controlled release drug delivery

Latest Headlines

Latest Headlines

Novan collects $7.8M from gov to develop nitric oxide burn med

Novan Therapeutics landed $78 million from the U.S. Biomedical Advanced Research and Development Authority to further develop the North Carolina-based company's technology that delivers nitric oxide gas to thermal wounds.

Ferring's labor-induction delivery platform passes PhIII muster

Ferring Pharmaceuticals bolstered its controlled-release, labor-induction delivery platform with Phase III data as the company awaits its approval from both European and U.S. authorities.

Nanosphere foam delivers drugs to the bladder

Researchers at the Institute of Plastics Processing (IKV) at RWTH Aachen University in Germany are developing a controlled-release foam that can deliver drugs to treat diseases such as overactive bladder.

With Éclat, Flamel gains regulatory brains, drug delivery pipeline

French drug delivery company Flamel Technologies ($FLML) is snatching up St. Louis-based Éclat Pharmaceuticals to access its specialty pharmaceutical and regulatory muscle for a planned expansion in the U.S. and elsewhere.

Columbia Labs won't give up on controlled-release vaginal gel

Columbia Laboratories is cutting 42% of its workforce and moving ahead with plans to advance a vaginal  progesterone gel, despite FDA's rejection of the product.

Sol-Gel seals $27M dermatology drug delivery deal with mystery partner

Israeli pharmaceutical company Sol-Gel Technologies says it nailed down a $27 million development and licensing deal with an as-yet unnamed U.S. pharmaceutical company regarding a "major"...

MicroCHIPS' wireless implantable device delivered osteoporosis drug in people

MicroCHIPS heavily promoted some long-awaited good news this week about its wireless, implantable drug delivery microchip. A small human trial proved that it can work in people, and the patients were...

Titan plans Q3 NDA submission for controlled-release implantable addiction treatment

Titan Pharmaceuticals ($TTNP) now envisions an NDA submission to the FDA for its implantable, controlled release treatment for opioid dependence during its fiscal 2012 third quarter. The South San...

Amylin gets FDA OK for weekly diabetes drug Bydureon

Say hello to Bydureon, a once-weekly injectable treatment for Type 2 diabetes finally approved by the FDA on Jan. 27. Amylin Pharmaceuticals ($AMLN) developed the drug using controlled release drug

Takeda abandons Euro rights to Durect's controlled-release pain drug

For the second time this year, Durect ($DRRX) faces a setback over its controlled-release anti-pain drug Posidur. The Cupertino, CA-based company disclosed that its European development and marketing